<DOC>
	<DOCNO>NCT01468207</DOCNO>
	<brief_summary>A study evaluate safety efficacy treatment adalimumab adult moderate severe hidradenitis suppurativa ( HS ) .</brief_summary>
	<brief_title>Efficacy Safety Study Adalimumab Treatment Hidradenitis Suppurativa</brief_title>
	<detailed_description>The clinical trial identifier PIONEER I . The purpose study evaluate safety adalimumab determine well work treatment adult moderate severe HS . HS chronic skin disease create red , swollen , painful bump break open combine form tunnel skin scar . Sometimes bumps heal quickly sometimes become much bad create sore heal multiple combined scar , area heal . In study , approximately 300 adult enrol treatment center worldwide . Subject participation study 50 week . There screen period , last 7 30 day , study treatment period 36 week . Study visit occur Screening , Baseline , Weeks 2 , 4 , 8 , 12 , 14 , 16 , 20 , 24 , 28 , 32 36 ( sooner subject leave study Week 36 ) . The study divide two treatment period . The first period ( Period A ) last 12 week second period ( Period B ) last 24 week .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adults must diagnosis HS least 1 year prior Baseline . HS lesion must present least two distinct anatomical area , one must least Hurley Stage II Hurley Stage III . Subject must stable HS least 60 day prior Screening visit Baseline visit . Subject must experience inadequate response least 90day treatment oral antibiotic treatment HS . Subject must total AN count great equal 3 baseline . Subject previously treat adalimumab another antitumor necrosis factor ( antiTNF ) therapy ( e.g. , infliximab etanercept ) . Subject receive oral antibiotic treatment HS within 28 day prior Baseline . Subject receive oral concomitant analgesic ( include opioids ) HSrelated pain within 14 day prior Baseline visit . If enter study concomitant oral analgesic nonHS related pain : Subject opioid analgesic within 14 day prior Baseline visit ; Subject stable dose nonopioid oral analgesic least 14 day prior Baseline visit ( `` need '' consider stable dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acne</keyword>
	<keyword>psoriasis</keyword>
	<keyword>hidradenitis suppurativa</keyword>
	<keyword>TNF</keyword>
	<keyword>HS</keyword>
	<keyword>PIONEER I</keyword>
	<keyword>acne inversa</keyword>
	<keyword>boil</keyword>
	<keyword>placebo control</keyword>
	<keyword>Double blind</keyword>
	<keyword>adalimumab</keyword>
</DOC>